Reviewing Myriad Genetics (NASDAQ:MYGN) and Lucira Health (NASDAQ:LHDXQ)

Financial News Live ·  May 2, 2023 10:13

Myriad Genetics (NASDAQ:MYGN – Get Rating) and Lucira Health (NASDAQ:LHDXQ – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.


This table compares Myriad Genetics and Lucira Health's net margins, return on equity and return on assets.

Get Myriad Genetics alerts:
Net Margins Return on Equity Return on Assets
Myriad Genetics -16.51% -5.83% -4.42%
Lucira Health -67.54% -13.55% -8.47%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Myriad Genetics and Lucira Health, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myriad Genetics 0 2 1 0 2.33
Lucira Health 0 0 0 0 N/A

Myriad Genetics currently has a consensus price target of $27.00, indicating a potential upside of 24.42%. Given Myriad Genetics' higher possible upside, equities research analysts plainly believe Myriad Genetics is more favorable than Lucira Health.

Earnings & Valuation

This table compares Myriad Genetics and Lucira Health's revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myriad Genetics $678.40 million 2.61 -$112.00 million ($1.39) -15.61
Lucira Health $93.06 million 0.01 -$64.83 million ($3.58) -0.01

Lucira Health has lower revenue, but higher earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than Lucira Health, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

99.1% of Myriad Genetics shares are owned by institutional investors. Comparatively, 57.0% of Lucira Health shares are owned by institutional investors. 1.8% of Myriad Genetics shares are owned by insiders. Comparatively, 30.4% of Lucira Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Myriad Genetics has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Comparatively, Lucira Health has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500.


Myriad Genetics beats Lucira Health on 9 of the 13 factors compared between the two stocks.

About Myriad Genetics

(Get Rating)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

About Lucira Health

(Get Rating)

Lucira Health Inc. is a medical technology company. It is focused on the development and commercialization of transformative and infectious disease test kits. Lucira Health Inc. is based in Emeryville, California.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment